title: Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.
abstract: Diabetes Mellitus continues to be a major non- communicable disease with global burden of 366 million at present and projected to increase to 439 to 552 million by 2030, India being the hub of diabetes. Sodium glucose transporter 2 (SGLT2) inhibitors presents a new class of anti-diabetic drugs having an insulin-independent mechanism that offers a considerable advantage of increasing urinary glucose excretion without inducing hypoglycemia and promoting weight loss due to loss of 300 to 400kcal/day, Canagliflozin being the 1(st) successful candidate of this group and became the first SGLT2 inhibitor to be FDA approved on March 29, 2013. In various clinical trials, it has shown promising results in controlling glycemia, causing weight loss, reducing systolic and diastolic BP and cardiovascular risk. There are some safety concerns associated with its use e.g. genital mycotic infections, increased urination, urinary tract infection and hyperkalemia, which need to be carefully addressed while using this drug.
authors.affiliation: Quantum Solutions India, DLF building, Chandigarh Technology Park, Chandigarh, India.
authors.forename: Shaveta
authors.initials: S
authors.lastname: Kaushal
authors.affiliation: Department of Pharmacology, AIIMS, New Delhi, India.
authors.forename: Harmanjit
authors.initials: H
authors.lastname: Singh
authors.affiliation: Central Leprosy Teaching and Research Institute, Chengalpattu, Tamilnadu, India.
authors.forename: Pugazhenthan
authors.initials: P
authors.lastname: Thangaraju
authors.affiliation: Department of Pharmacology, Govt. Medical College Patiala, Punjab, India.
authors.forename: Jasbir
authors.initials: J
authors.lastname: Singh
keywords: Canagliflozin; Diabetes Mellitus; HbA1C; Inhibitors; SGLT2
references.citation: Eur Heart J. 2011 Aug;32(15):1832-4
references.pmid: 21471136
references.citation: Diabetes Care. 2009 Jan;32(1):193-203
references.pmid: 18945920
references.citation: Nephrol Dial Transplant. 2008 Dec;23(12):3874-9
references.pmid: 18622023
references.citation: Int J Clin Pract. 2006 Oct;60(10):1272-80
references.pmid: 16981971
references.citation: Lancet. 1998 Sep 12;352(9131):837-53
references.pmid: 9742976
references.citation: PLoS One. 2012;7(2):e30555
references.pmid: 22355316
references.citation: Lancet. 1998 Sep 12;352(9131):854-65
references.pmid: 9742977
references.citation: Diabetes Res Clin Pract. 2011 Dec;94(3):311-21
references.pmid: 22079683
references.citation: Curr Diab Rep. 2010 Apr;10(2):101-7
references.pmid: 20425568
references.citation: Diabetes Care. 2011 Jun;34(6):1337-43
references.pmid: 21505207
references.citation: Eur Heart J. 2011 Aug;32(15):1900-8
references.pmid: 21471135
references.citation: Lancet. 2013 Sep 14;382(9896):941-50
references.pmid: 23850055
references.citation: Eur J Pharmacol. 2009 Sep 15;618(1-3):98-104
references.pmid: 19615995
references.citation: Diabetes Obes Metab. 2012 Jan;14(1):77-82
references.pmid: 21883806
references.citation: Diabetes Metab Res Rev. 2005 Jan-Feb;21(1):31-8
references.pmid: 15624123
references.citation: J Clin Invest. 1987 May;79(5):1510-5
references.pmid: 3571496
references.citation: Diabetes Obes Metab. 2013 Apr;15(4):372-82
references.pmid: 23279307
references.citation: Circulation. 1999 Sep 7;100(10):1134-46
references.pmid: 10477542
references.citation: Diabetes Obes Metab. 2008 Jul;10(7):545-55
references.pmid: 18518892
references.citation: Eur J Pharmacol. 2009 May 1;609(1-3):148-54
references.pmid: 19281809
references.citation: Diabetes Care. 2013 Sep;36(9):2508-15
references.pmid: 23564919
references.citation: Scand J Clin Lab Invest. 1971 Sep;28(1):101-9
references.pmid: 5093515
references.citation: Diabetes Obes Metab. 2013 May;15(5):463-73
references.pmid: 23464594
references.citation: Diabetes Technol Ther. 2011 Nov;13(11):1145-54
references.pmid: 21751887
references.citation: Lancet. 2011 Jul 9;378(9786):182-97
references.pmid: 21705062
references.citation: Kidney Int. 2009 Jun;75(12):1272-1277
references.pmid: 19357717
references.citation: Clin Pharmacol Ther. 2009 May;85(5):520-6
references.pmid: 19129748
references.citation: BMJ. 2009 May 19;338:b1665
references.pmid: 19454737
references.citation: J Clin Pharmacol. 2013 Jun;53(6):601-10
references.pmid: 23670707
references.citation: Diabetes Care. 2012 Jun;35(6):1232-8
references.pmid: 22492586
references.citation: Diabetes Obes Metab. 2011 Jul;13(7):669-72
references.pmid: 21457428
references.citation: N Engl J Med. 2007 Jun 14;356(24):2457-71
references.pmid: 17517853
references.citation: N Engl J Med. 2008 Oct 9;359(15):1565-76
references.pmid: 18784091
references.citation: J Intern Med. 2007 Jan;261(1):32-43
references.pmid: 17222166
references.citation: Diabetes Obes Metab. 2012 Jun;14(6):539-45
references.pmid: 22226086
references.citation: Diabetes Obes Metab. 2012 Jan;14(1):5-14
references.pmid: 21955459
references.citation: Kidney Int Suppl. 2011 Mar;(120):S20-7
references.pmid: 21358698
references.citation: Diabetes Res Clin Pract. 2010 Jan;87(1):4-14
references.pmid: 19896746
references.citation: Curr Pharm Des. 2001 Apr;7(6):417-50
references.pmid: 11281851
references.citation: N Engl J Med. 2008 Oct 9;359(15):1577-89
references.pmid: 18784090
references.citation: Diabetologia. 2009 Nov;52(11):2288-98
references.pmid: 19655124
references.citation: Diabetes Care. 2001 Feb;24(2):382-91
references.pmid: 11213896
references.citation: J Med Chem. 2010 Sep 9;53(17):6355-60
references.pmid: 20690635
references.citation: Pflugers Arch. 2004 Feb;447(5):510-8
references.pmid: 12748858
references.citation: Diabetes Care. 2012 Jan;35 Suppl 1:S11-63
references.pmid: 22187469